Diamyd Medical

The Board of Directors in Diamyd Medical resolved on February 28, 2025, pursuant to the authorization granted by the Company's annual general meeting held on December 5, 2024, on a rights issue of up to approximately SEK 208 million.

Preliminary outcome following the updated preliminary results
The preliminary outcome indicates that approximately 16 million units, of which approximately 0.4 million comprise of units containing A-shares, corresponding to approximately 61 percent of the offered units, have been subscribed for with unit rights in the Rights Issue. Additionally, applications for subscription of approximately 12 million B-units without unit rights, corresponding to approximately 46 percent of the offered units, have been received. Thus, the preliminary outcome indicates that the Rights Issue have been subscribed with the support of unit rights and subscription applications without the support of unit rights to approximately 108 percent. Through the Rights Issue, the Company will therefore receive approximately SEK 205 million before the deduction of costs attributable to the Rights Issue. The Rights Issue is not subject to costs for underwriting commitments.

Exercise of the Additional Unit Issue
In connection with the Company's announcement on February 28, 2025, that the Board of Directors had resolved on the Rights Issue, the Board of Directors also communicated its intention to resolve on an additional unit issue of up to 2,500,000 B-units, corresponding to additional issue proceeds of up to SEK 20 million, in the event that the B-units offered in the Rights Issue were fully subscribed. The purpose was to meet a higher-than-anticipated demand and to provide the Company with additional capital. Due to the strong interest in the Rights Issue, the Board of Directors will resolve on the Additional Unit Issue up to the amount subscribed in excess of the full subscription of the total amount of B-units offered in the Rights Issue. Consequently, approximately 2.3 million B-units will be issued in the Additional Unit Issue. Allotment in the Additional Unit Issue will be made at the discretion of the Board of Directors and will primarily target existing shareholders and strategic investors who subscribed for units in the Rights Issue but did not receive full allotment. The Additional Unit Issue will therefore increase the total issue proceeds from the Rights Issue to approximately SEK 224 million before related issue costs.

Notice of allotment
All those who have subscribed for units without unit rights will be allocated units in accordance with the principles set out in the EU growth prospectus which was approved and registered by the Swedish Financial Supervisory Authority on April 14, 2025. Notice of allotment to the persons who subscribed for units without unit rights is expected to be distributed on April 30, 2025. Subscribed and allotted units shall be paid in cash within three banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed for units through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted units will be notified.

Final outcome and trading in BTU's
The final outcome of the Rights Issue is expected to be published around April 30, 2025. The last day of trading in paid subscribed units (Sw. BTU B) is expected to be May 20, 2025. The new B-shares and TO 5 B subscribed for with and without unit rights are expected to be traded on Nasdaq First North Growth Market around May 26, 2025.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the Rights Issue. Aqurat Fondkommission AB has been appointed as Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd^® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. An early read-out of the Phase 3 trial is expected in March 2026. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group - both in a largescale meta-analysis as well as in the Company's prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.